A

Axiom Bio

AI-driven hepatotoxicity prediction for drugs

Computational Scientist - Chemistry

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timeSouth San Francisco, CA, USANo salary listedIn-person

About the Job

Requirements

  • An advanced degree in chemistry, computational chemistry, cheminformatics, or a related field, or equivalent experience in drug discovery.
  • A background in machine learning for chemistry, computational chemistry, medicinal chemistry, or cheminformatics, with the ability to work across disciplines.
  • Strong Python skills and fluency with RDKit, NumPy, pandas, and SQL for scientific computing and chemical data analysis.
  • Strong computational chemistry, software engineering, and machine learning skills, with experience building and using AI agents for scientific work.
  • Use agents in research, coding, and analysis; verify their outputs and recognize when they need better tools or context.
  • Interest in building agent evaluations, benchmarks, and reinforcement learning environments grounded in experimental evidence and expert judgment.
  • Experience partnering with medicinal chemists and drug discovery scientists to guide decisions on active drug programs.
  • Ability to analyze large chemical datasets, apply sound statistical reasoning, and draw conclusions grounded in chemistry.
  • Communicate scientific work through presentations, reports, and discussions, and manage relationships with biotech and pharmaceutical partners.
  • Knowledge of LLM APIs, agent tool development, multi-agent workflows, context management, and scientific evidence retrieval.
  • Knowledge of agent evaluation, trace analysis, failure diagnosis, and reinforcement learning environments with experimentally grounded rewards.
  • Knowledge of molecular property prediction, chemical representations, generative models, active learning, and multi-parameter optimization.
  • Knowledge of virtual library enumeration, synthetic feasibility assessment, patent mining, and structure–activity analysis.
  • Knowledge of statistical analysis of potency, ADME, toxicity, imaging, transcriptomic, and mass spectrometry data.
  • Knowledge of integration of agents and computational tools with experimental workflows, including compound selection, assay planning, and iterative learning from results.

Responsibilities

  • Work with senior drug discovery scientists to build and use AI agents that design compounds, test hypotheses, and advance safer, more effective drugs.
  • Equip agents with molecular modeling, machine learning, and cheminformatics tools to optimize potency, selectivity, safety, and drug-like properties.
  • Develop agent workflows that analyze chemical and biological data, uncover structure–activity relationships, and guide each design round.
  • Build agents that search literature and patents, synthesize evidence, propose molecules, and prioritize informative experiments.
  • Connect agents to synthesis and assay workflows so they can learn from experimental results and iteratively improve their designs.
  • Evaluate agent reasoning and predictions against experimental evidence, investigate failures, and improve their tools and decision-making.
  • Turn experimental campaigns into benchmarks and reinforcement learning environments that teach frontier models scientific reasoning and molecular design.
  • Bring successful agents and tools into Translate and workflows used by Axiom’s scientists and pharmaceutical partners.

About the Company

Axiom Bio

AI-driven hepatotoxicity prediction for drugs

Axiom Bio provides an AI-driven platform for predictive toxicology that helps drug researchers identify potential liver toxicity early in development. The platform uses a large proprietary dataset—over 115,000 small molecules screened on primary human liver cells with imaging and biochemical readouts, plus PK and clinical data—to predict drug-induced liver injury and related toxicity pathways from a molecule’s structure. It differentiates itself through its large human-toxicity dataset and by offering mechanistic insights (such as mitochondrial toxicity, ER stress, and ROS) at a low per-molecule cost. The goal is to speed up safe drug development by de-risking preclinical pipelines and reducing reliance on animal testing.

Company size
11-50
Company stage
Seed
Total funding
$15M
Headquarters
San Francisco, CA
Founded
2024

Recently Posted Jobs

Explore more opportunities at Axiom Bio

See more jobs